ObsErvationAl Study to analYse titration of the new Diamicron MR 60 mg formulation in daily clinical practice in a large population with uncontrolled type 2 diabetes
| ISRCTN | ISRCTN00943368 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN00943368 |
| Secondary identifying numbers | DME-5702-149 |
- Submission date
- 07/02/2013
- Registration date
- 25/02/2013
- Last edited
- 16/04/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Gliclazide is a well-known drug prescribed to control glucose levels in patients with type 2 diabetes mellitus. Diamicron MR 60 mg is a new modified-release formulation of gliclazide that enables the number of tablets per intake to be halved and allows gradual increase of dosage up to an optimal level. This new formulation is also expected to enhance compliance, meaning that more patients take their treatment properly and have better control of their diabetes.
The aim of the ongoing EasyDia program is to analyse how the new formulation Diamicron MR 60 mg is prescribed in daily clinical practice, notably of how rapidly and easily patients reach the optimal dosage.
Who can participate?
EasyDia is including over 5000 male or female patients aged 35 years or older with type 2 diabetes with glucose levels that are poorly controlled with diet or lifestyle measures or with other antidiabetic treatments (except insulin).
What does the study involve?
This is an observational study, which means that included patients are managed in exactly the same way as they would be if they were not participating in the program.
What are the possible benefits and risks of participating?
There should be no net benefit or risk for the participants as this is an observational study in which the participants will be treated as in normal practice. It should be noted that gliclazide has been in clinical use in other formulations since 40 years, and is not associated with any untoward safety issues.
Where is the study run from?
The study in taking place in 8 countries (Armenia, Russia, Switzerland, Malaysia, Georgia, The Lebanon, Slovenia, and Bangladesh) and all investigators are physicians in general practice or hospitals.
When is the study starting and how long is it expected to run for?
The first patient visit was in July 2011 and the study is expected to end in October 2013.
Who is funding the study?
The study is being funded by the French pharmaceutical company Servier.
Who is the main contact?
Manuel Ruiz
manuel.ruiz@fr.netgrs.com
Contact information
Scientific
Division of Endocrinology and Metabolism
St Michael's Hospital
61 Queen St East #6121
Toronto
M5C 2T2
Canada
Study information
| Study design | Multicenter open-label observational study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Non randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Other |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | ObsErvationAl Study to analYse titration of Diamicron MR 60 mg in daily clinical practice in a large population with uncontrolled type 2 diabetes |
| Study acronym | EASYDia |
| Study objectives | A new formulation of modified-release gliclazide 60 mg (Diamicron MR 60 mg) has been developed with the aim of allowing gradual uptitration to optimal dosage as well as halving the number of tablets per administration at maintenance dosage. This 6-month, multicenter, open-label, non-randomized, non-comparative, observational study was designed to assess the prescription of gliclazide MR 60 mg in primary care, notably during the titration phase of treatment. |
| Ethics approval(s) | Slovenian National Medical Ethics Committee, 19/10/2011 All other centres will seek ethics approval before recruiting participants |
| Health condition(s) or problem(s) studied | Type 2 diabetes mellitus |
| Intervention | This observational study is performed in patients receiving gliclazide MR 60 mg as the basis of their treatment strategy: 1. Newly diagnosed patients will be initiated on gliclazide MR 60 mg. 2. Previously diagnosed patients will be switched to gliclazide MR 60 mg or receive it added on to their current treatment. The starting dose of gliclazide MR 60 mg will be defined according to the judgment of the investigators and the Summary of Product Characteristics. Dose increases will be made at each study visit (1, 2, and 3 months) according to fasting plasma glucose and patient characteristics (especially regarding elderly patients or those with renal insufficiency), up to a maximal dose of 120 mg (2 tablets) per day in a single intake at breakfast, before adding any other oral antidiabetic drug. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Diamicron MR 60 mg (gliclazide 60 mg) |
| Primary outcome measure | Time to reach the efficient dose that provides optimal glycemic control, according to the investigator's judgment |
| Secondary outcome measures | 1. Average daily dose of gliclazide MR 60 mg at the end of the study 2. Compliance assessed by a qualitative questionnaire (addressed to the investigators) 3. Treatment doses: repartition of each dose level in the population over time 4. Efficacy parameters (HbA1c and fasting plasma glucose): change versus baseline; percentage of patients achieving an HbA1c level 6.5% or lower, and 7% or lower 5. Safety parameters 6. Treatment acceptability with assessment of body weight change |
| Overall study start date | 01/07/2011 |
| Completion date | 31/10/2013 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 5000 |
| Key inclusion criteria | Male or female patients with type 2 diabetes, aged 35 years or older, not optimally controlled (HbA1c 7.5% or higher, according to patient profile), including: 1. Newly diagnosed patients, in whom lifestyle recommendations have failed 2. Previously diagnosed patients, who are intolerant or have contraindication to current treatment, or in whom previous treatment has failed. |
| Key exclusion criteria | 1. Requirement for insulin therapy 2. Severe liver or renal failure 3. Contraindication to gliclazide 4. Pregnancy or breast feeding 5. Treatment with miconazole |
| Date of first enrolment | 01/07/2011 |
| Date of final enrolment | 31/10/2013 |
Locations
Countries of recruitment
- Armenia
- Bangladesh
- Canada
- Georgia
- Lebanon
- Malaysia
- Russian Federation
- Slovenia
- Switzerland
Study participating centre
M5C 2T2
Canada
Sponsor information
Industry
50 rue Carnot
Suresnes
92284
France
| Website | http://www.servier.com/ |
|---|---|
"ROR" |
https://ror.org/034e7c066 |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 10/04/2018 | Yes | No |
Editorial Notes
16/04/2018: Publication reference added.
